Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Treatment Intensification in Patients With High Risk Mantle Cell Lymphoma Using CAR-T-cell Treatment After an Abbreviated Induction Therapy With Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) as Compared to Standard of Care Induction and Maintenance (Arm B)

NCT06482684 is registered in ClinicalTrials.gov with Christian Schmidt, MD as lead sponsor.

NCT NCT06482684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06482684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Treatment Intensification in Patients With High Risk Mantle Cell Lymphoma Using CAR-T-cell Treatment After an Abbreviated Induction Therapy With Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) as Compared to Standard of Care Induction and Maintenance (Arm B)
Lead sponsor
Christian Schmidt, MD
Phase
Phase 2
Overall status
Recruiting
Start date
February 15, 2024
Completion date
December 31, 2031
Enrollment
150 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma